Your browser doesn't support javascript.
loading
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura, Michinori; Ishizawa, Kenichi; Maruyama, Dai; Uike, Naokuni; Ando, Kiyoshi; Izutsu, Koji; Terui, Yasuhito; Imaizumi, Yoshitaka; Tsukasaki, Kunihiro; Suzuki, Kenshi; Izumi, Tohru; Usuki, Kensuke; Kinoshita, Tomohiro; Taniwaki, Masafumi; Uoshima, Nobuhiko; Suzumiya, Junji; Kurosawa, Mitsutoshi; Nagai, Hirokazu; Uchida, Toshiki; Fukuhara, Noriko; Choi, Ilseung; Ohmachi, Ken; Yamamoto, Go; Tobinai, Kensei.
Afiliação
  • Ogura M; Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan. mi-ogura@naa.att.ne.jp.
  • Ishizawa K; Department of Hematology, Tokai Central Hospital, 4-6-2 Higashijimacho, Sohara, Kakamigahara, Gifu, 504-8601, Japan. mi-ogura@naa.att.ne.jp.
  • Maruyama D; Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Uike N; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • Ando K; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Izutsu K; Department of Hematology and Oncology, Tokai University Hospital, Isehara, Japan.
  • Terui Y; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Imaizumi Y; Department of Hematology Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Tsukasaki K; Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
  • Suzuki K; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Izumi T; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Usuki K; Division of Hematology, Tochigi Cancer Center, Utsunomiya, Japan.
  • Kinoshita T; Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
  • Taniwaki M; Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
  • Uoshima N; Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Suzumiya J; Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan.
  • Kurosawa M; Department of Oncology/Hematology, School of Medicine, Shimane University, Izumo, Japan.
  • Nagai H; Department of Hematology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
  • Uchida T; Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Fukuhara N; Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
  • Choi I; Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Ohmachi K; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Yamamoto G; Department of Hematology and Oncology, Tokai University Hospital, Isehara, Japan.
  • Tobinai K; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Int J Hematol ; 105(4): 470-477, 2017 Apr.
Article em En | MEDLINE | ID: mdl-27900638
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Linfoma de Célula do Manto / Cloridrato de Bendamustina / Rituximab Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B / Linfoma de Célula do Manto / Cloridrato de Bendamustina / Rituximab Idioma: En Ano de publicação: 2017 Tipo de documento: Article